Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81
Document › Details

Sanofi S.A.. (3/29/13). "Press Release: Sanofi to Invest USD 75 Million in a New Manufacturing Facility in Vietnam". Paris.

Region Region Ho Chi Minh City (Saigon)
  Country Vietnam
Organisations Organisation Sanofi Vietnam
  Organisation 2 Vinapharm (VN)
Product Product pharmaceutical
Person Person Viehbacher, Christopher A. (Chris) (Bertarelli Group 201510 Managin Partner Gurnet Point Capital before Sanofi + GSK)

Sanofi (EURONEXT: SAN and NYSE: SNY) announces today the official launch of a construction project for a new manufacturing facility in the Saigon High Tech Park - Ho Chi Minh City, during a ceremony in the presence of Christopher A. Viehbacher, Chief Executive Officer of Sanofi. The new state-of-the-art plant will expand Sanofi's manufacturing capacity in Vietnam to meet the fast growing demand of the Vietnamese pharmaceutical market and will serve as an export platform to ASEAN(*) countries.

The investment in this new plant will amount to USD 75 million and will constitute Sanofi's largest investment in Vietnam to date. With an initial capacity of 90 million units per year - and a possible extension up to 150 million units - the facility will produce high-quality pharmaceuticals and consumer healthcare products. The plant is scheduled to be fully operational by the end of 2015 and will join Sanofi's existing network of 40 manufacturing sites in Emerging Markets.

"This new production and development center is the largest investment ever made by Sanofi in Vietnam and illustrates our commitment to bringing high quality medicines to a broader population in Vietnam", said Christopher A. Viehbacher, Chief Executive Officer of Sanofi. "Sanofi has been present in Vietnam for more than 50 years and has built the number 1 position in one of the most dynamic South East Asian countries. This new investment will contribute to further strengthen Sanofi's leadership position in Emerging Markets".

(*) ASEAN: Association of South East Asian Nations

About Sanofi in Vietnam

Sanofi Vietnam head office is located in Ho Chi Minh City. Its products have been present in Vietnam for more than 50 years. The company currently has about 1,200 employees working nationwide. Sanofi is the only foreign pharmaceutical company with two WHO-GMP certified manufacturing facilities in Ho Chi Minh City, manufacturing 80% of the volume of Sanofi products marketed in Vietnam. The long history, wide product portfolio, and leading position in the country give Sanofi a unique expertise to answer the patients' needs in Vietnam. Sanofi has established a strong partnership with Vinapharm since 1993. In 2012, Sanofi Vietnam is the market leader with a market share of 4%. For more detail information, please visit website:

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information, please visit website:

Sanofi Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2012. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Relations Presse
Jean-Marc Podvin
Tél. : +33 (0) 1 53 77 46 46
E-mail :

Relations Investisseurs
Sébastien Martel
Tél. : +33 (0) 1 53 77 45 45
E-mail :

Record changed: 2019-06-09


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Made Without Love 650x80px

» top